Cap: $32.8M
Runway: Q2 2027
Clinical Pipeline (Compendium View)
| Asset | Indication | Stage | Next Catalyst |
|---|---|---|---|
| Iomab-B | BMT Conditioning (AML) | Phase 3 (Post-CRL) | FDA Type A Meeting: Q2 2026 |
| Actimab-A | Relapsed/Refractory AML | Phase 1/2 | Dose Escalation Data: Q3 2026 |
Latest SEC Filings
Active Clinical Trials
Operational Overview
Operational Overview
Actinium remains a high-conviction, high-risk play in the targeted radiotherapy space. After the 2024 CMC-related setbacks, the focus has shifted entirely to the regulatory path for Iomab-B and the promising “Actimab-A” + CLAG-M combination.
Analyst Note
The current valuation ($~33M$) suggests the market has completely written off the Iomab-B BLA. Any positive signal from the FDA regarding a path to filing without a new trial would represent a massive re-rating event.